Eliem Therapeutics Inc

NASDAQ ELYM

Data sourced from

and

Download Data

Eliem Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2024: USD 105.03 M

Eliem Therapeutics Inc Cash and Short-Term Investments is USD 105.03 M for the quarter ending March 31, 2024, a -3.97% change year over year. Cash and Short-Term Investments is the sum of cash and short-term investments, representing the company's liquid assets.

Eliem Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2023 was USD 109.37 M, a -11.75% change year over year.
Eliem Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2022 was USD 123.94 M, a 158.69% change year over year.
Eliem Therapeutics Inc Cash and Short-Term Investments for the quarter ending March 31, 2021 was USD 47.91 M.

NASDAQ: ELYM

Eliem Therapeutics Inc

CEO	Mr. Robert W. Azelby M.B.A.
IPO Date	Aug. 10, 2021
Location	United States
Headquarters	23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees	9
Sector	Healthcare
Industry	Biotechnology

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key trends